Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review.
Francesco PiccirilloPaola LiporaceAnnunziata NuscaVincenzo NafisioAndrea CorlianòFrancesca MagaròRaffaele Antonelli IncalziGian Paolo UssiaFrancesco GrigioniPublished in: Journal of cardiovascular development and disease (2023)
Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes.
Keyphrases
- high speed
- chronic kidney disease
- cardiovascular events
- cardiovascular disease
- end stage renal disease
- type diabetes
- contrast enhanced
- coronary artery disease
- anti inflammatory
- glycemic control
- oxidative stress
- magnetic resonance
- healthcare
- systemic sclerosis
- left ventricular
- early onset
- metabolic syndrome
- mass spectrometry
- idiopathic pulmonary fibrosis